Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | WDR5 | P61964 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26081558 | 0.91 | MAPT (0.52) | SMN1; SMN2MAPTWDR5L3MBTL1NQO2 | |
| SCHEMBL1148180 | 0.84 | — | — | |
| SCHEMBL19534179 | 0.83 | MEN1 (0.61) | MAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL22514309 | 0.81 | PRSS1 (0.50) | SMN1; SMN2MAPTWDR5MMP3BCL2L1 | |
| SCHEMBL18644564 | 0.81 | NOS3 (0.39) | MAPTL3MBTL1HPGDALDH1A1RAB9A | |
| SCHEMBL16902370 | 0.81 | PRSS1 (0.60) | SMN1; SMN2MAPTWDR5 | |
| SCHEMBL13754825 | 0.79 | PRSS1 (0.64) | SMN1; SMN2MAPTWDR5 | |
| SCHEMBL40527 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTWDR5L3MBTL1MMP3 | |
| SCHEMBL23268269 | 0.78 | HSD17B1 (0.37) | SMN1; SMN2MAPTWDR5NQO2HPGD | |
| SCHEMBL26081554 | 0.78 | PRSS1 (0.62) | SMN1; SMN2MAPTWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11552258-B2 | Organic light-emitting device comprising emission layer satisfying specific singlet excitation energy level conditions | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-01-10 | — | — | US | disclosed |
| EP-3764416-B1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO LTD (KR) | 2022-01-26 | — | — | EP | disclosed |
| EP-3903583-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | BASF SE (DE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3903581-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS I | BASF SE (DE) | 2021-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11552258-B2 | Organic light-emitting device comprising emission layer satisfying specific singlet excitation energy level conditions | EML4, NES, TBL2 | SMN1; SMN2 1179/4885MAPT 141/4885WDR5 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.